RxDoctor Payments Data

Henry de Jesus-De la Cruz

Gastroenterology · Bayamon, PRNPI 1174940068

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,528 of the $8,112 with a category attached, or 68.1%. 15 manufacturers reported payments, led by Johnson & Johnson at 39.0% of the total. Reporting peaked in 2024 at $3,945 and has fallen 72.0% since, to $1,104 in 2025.

$8,112in general payments, 2019–2025

Across 135 payments — averaging $60.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • AbbVie$2K
  • Gilead$834
  • E.r. Squibb & Sons, L.L.C.$521
  • Olympus Latin America, Inc.$209
  • Boston Scientific$201
  • plus $859 from 9 others

What the payments were for

  • Consulting fees$2,27528%
  • Travel & lodging$3094%
  • Food & beverage$5,52868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,112 in reported general payments places this provider in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,366
Medicare patients
24
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuprepSodium, Potassium,mag Sulfates369$43,334
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates263$20,898
CreonLipase/Protease/Amylase13$15,554
LinzessLinaclotide16$8,771
Naloxone Hcl669$8,358
Sucralfate120$6,408
Dexlansoprazole DrDexlansoprazole25$5,698
Famotidine720$5,636
Pantoprazole Sodium584$4,542
Colestipol Hcl63$3,028
Tetracycline Hcl21$3,011
Sodium Chloride0.9 % Sodium Chloride588$2,795
Clarithromycin64$2,523
Omeprazole340$2,489
Lubiprostone14$2,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,324$24,32529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →